# COVID-19 VaccinE Response in Rheumatology Patients

> **NCT05080218** · PHASE4 · COMPLETED · sponsor: **Jeffrey Curtis** · enrollment: 841 (actual)

## Conditions studied

- Rheumatoid Arthritis
- Psoriatic Arthritis
- Spondylarthritis

## Interventions

- **DRUG:** Upadacitinib
- **DRUG:** Abatacept
- **DRUG:** Secukinumab
- **DRUG:** Tofacitinib
- **DRUG:** TNF Inhibitor
- **DRUG:** Canakinumab Injection
- **DRUG:** Baricitinib
- **DRUG:** Ixekizumab

## Key facts

- **NCT ID:** NCT05080218
- **Lead sponsor:** Jeffrey Curtis
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-15
- **Primary completion:** 2024-04-04
- **Final completion:** 2024-05-28
- **Target enrollment:** 841 (ACTUAL)
- **Last updated:** 2025-05-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05080218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05080218, "COVID-19 VaccinE Response in Rheumatology Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05080218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*